{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:29Z","timestamp":1794047489646,"version":"4.8.0"},"reference-count":14,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285380","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:08:54Z","timestamp":1727953734000},"page":"488-492","source":"Crossref","is-referenced-by-count":0,"title":["Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile"],"prefix":"10.3324","volume":"110","author":[{"given":"Paul","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Paba","family":"Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"72404","doi-asserted-by":"crossref","unstructured":"Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anti-cancer therapy?. Cell Cycle. 2008; 7(2):188-193.","DOI":"10.4161\/cc.7.2.5326"},{"key":"72405","doi-asserted-by":"crossref","unstructured":"Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006; 355(12):1253-1261.","DOI":"10.1056\/NEJMra061808"},{"key":"72406","doi-asserted-by":"crossref","unstructured":"Jordan CT, Upchurch D, Szilvassy SJ. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-1784.","DOI":"10.1038\/sj.leu.2401903"},{"key":"72407","doi-asserted-by":"crossref","unstructured":"Ray A, Das DS, Ravillah D. SL-401, a novel targeted therapy directed to the interleukin-3 receptor (IL-3R), blocks plasmacytoid dendritic cell (pDC)-triggered myeloma cell growth and prevents osteoclastogenesis. Blood. 2014; 124(21):3441.","DOI":"10.1182\/blood.V124.21.3441.3441"},{"key":"72408","doi-asserted-by":"crossref","unstructured":"Frankel AE, Woo JH, Ahn C. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014; 124(3):385-392.","DOI":"10.1182\/blood-2014-04-566737"},{"key":"72409","doi-asserted-by":"crossref","unstructured":"Vergez F, Green AS, Tamburini J. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011; 96(12):1792-1798.","DOI":"10.3324\/haematol.2011.047894"},{"key":"72410","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Mughal TI, Brooks C, Lindsay R, Pemmaraju N. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leuk Lymphoma. 2021; 62(11):2568-2586.","DOI":"10.1080\/10428194.2021.1927021"},{"key":"72411","doi-asserted-by":"crossref","unstructured":"Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008; 49(3):543-553.","DOI":"10.1080\/10428190701799035"},{"key":"72412","doi-asserted-by":"crossref","unstructured":"Durie BG, Harousseau JL, Miguel JS. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9):1467-1473.","DOI":"10.1038\/sj.leu.2404284"},{"key":"72413","doi-asserted-by":"crossref","unstructured":"Miguel JS, Weisel K, Moreau P. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066.","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"72414","unstructured":"Stemline Therapeutics, Inc.. ELZONRIS\u00ae (tagraxofusp-erzs) prescribing information. 2023."},{"key":"72415","doi-asserted-by":"crossref","unstructured":"Dechow T, Aldaoud A, Behlendorf T. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Eur J Haematol. 2022; 108(2):133-144.","DOI":"10.1111\/ejh.13719"},{"key":"72416","doi-asserted-by":"crossref","unstructured":"Richardson PG, Siegel DS, Vij R. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123(12):1826-1832.","DOI":"10.1182\/blood-2013-11-538835"},{"key":"72417","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285380\/77607","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285380\/78045","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11769\/77607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:23Z","timestamp":1794046043000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285380","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}